A healthier approach to clinical trials evaluating resveratrol for primary prevention of age-related diseases in healthy populations

Aging

Volumn 5, Issue 7, 2013, Pages 495-506

  Smoliga, James M ^a   Sage Colombo, E ^b   Campen, Matthew J ^b  

^a HIGH POINT UNIVERSITY   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Biomarker; Biosensor; Cardiovascular disease; Nutraceutical; Sirtuin; Vascular cell adhesion molecule

Indexed keywords

EID: 84881104932     PISSN: 19454589     EISSN: None     Source Type: Journal    
DOI: 10.18632/aging.100579     Document Type: Article

References (98)

1. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006; 444:337-342.
2. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008; 8:157-168.
3. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, Tatar M and Sinclair D. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature. 2004; 430:686-689.
4. Timmers S, Auwerx J and Schrauwen P. The journey of resveratrol from yeast to human. Aging (Albany NY). 2012; 4:146-158.
5. Baur JA, Ungvari Z, Minor RK, Le Couteur DG and de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov. 2012; 11:443-461.
6. Rossi D, Guerrini A, Bruni R, Brognara E, Borgatti M, Gambari R, Maietti S and Sacchetti G. trans-Resveratrol in nutraceuticals: issues in retail quality and effectiveness. Molecules (Basel, Switzerland). 2012; 17:12393-12405.
7. Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB, Gu C, Kunz I, Rossi Fanelli F, Patterson BW and Klein S. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012; 16:658-664.
8. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, Moller N, Jessen N, Pedersen SB and Jorgensen JO. High-Dose Resveratrol Supplementation in Obese Men: An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition. Diabetes. 2013; 62:1186-1195.
9. Agarwal B, Campen MJ, Channell MM, Wherry SJ, Varamini B, Davis JG, Baur JA and Smoliga JM. Resveratrol for primary prevention of atherosclerosis: Clinical trial evidence for improved gene expression in vascular endothelium. Int J Cardiol. 2013; 166:246-248.
10. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011; 14:612-622.
11. AbuMweis SS, Jew S and Jones PJ. Optimizing clinical trial design for assessing the efficacy of functional foods. Nutr Rev. 2010; 68:485-499.
12. Morris MC and Tangney CC. A potential design flaw of randomized trials of vitamin supplements. JAMA. 2011; 305:1348-1349.
13. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB and Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. The New England journal of medicine. 2006; 355:2631-2639.
14. Blagosklonny MV. Validation of anti-aging drugs by treatingage-related diseases. Aging (Albany NY). 2009; 1:281-288.
15. Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P,Hawkins M, Cohen HW and Barzilai N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci. 2012; 67:1307-1312.
16. Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B, Cseh J,Mikolas E, Szijarto IA, Merei A, Halmai R, Meszaros LG, Sumegi B and Wittmann I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011:1-7.
17. Magyar K, Halmosi R, Palfi A, Feher G, Czopf L, Fulop A, Battyany I, Sumegi B, Toth K and Szabados E. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc. 2012; 50:179-187.
18. Tome-Carneiro J, Gonzalvez M, Larrosa M, Yanez-Gascon MJ, Garcia-Almagro FJ, Ruiz-Ros JA, Tomas-Barberan FA, Garcia-Conesa MT and Espin JC. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebocontrolled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2013; 27:37-48.
19. Zahedi HS, Jazayeri S, Ghiasvand R, Djalali M and Eshraghian MR. Effects of polygonum cuspidatum containing resveratrol on inflammation in male professional basketball players. International journal of preventive medicine. 2013; 4:S1-4.
20. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R and Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380:581-590.
21. Tonelli M, Lloyd A, Clement F, Conly J, Husereau D, Hemmelgarn B, Klarenbach S, McAlister FA, Wiebe N and Manns B. Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ. 2011; 183:E1189-1202.
22. Kotwal S, Jun M, Sullivan D, Perkovic V and Neal B. Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circulation Cardiovascular quality and outcomes. 2012; 5:808-818.
23. Myung SK, Ju W, Cho B, Oh SW, Park SM, Koo BK and Park BJ. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2013; 346:f10.
24. Marchal J, Blanc S, Epelbaum J, Aujard F and Pifferi F. Effects of chronic calorie restriction or dietary resveratrol supplementation on insulin sensitivity markers in a primate, Microcebus murinus. PLoS One. 2012; 7:e34289.
25. Rascon B, Hubbard BP, Sinclair DA and Amdam GV. The lifespan extension effects of resveratrol are conserved in the honey bee and may be driven by a mechanism related to caloric restriction. Aging (Albany NY). 2012; 4:499-508.
26. Joseph AM, Malamo AG, Silvestre J, Wawrzyniak N, Carey- Love S, Nguyen LM, Dutta D, Xu J, Leeuwenburgh C and Adhihetty PJ. Short-term caloric restriction, resveratrol, or combined treatment regimens initiated in late-life alter mitochondrial protein expression profiles in a fiber-type specific manner in aged animals. Experimental gerontology. 2013; 48:858-868.
27. Antosh M, Whitaker R, Kroll A, Hosier S, Chang C, Bauer J, Cooper L, Neretti N and Helfand SL. Comparative transcriptional pathway bioinformatic analysis of dietary restriction, Sir2, p53 and resveratrol life span extension in Drosophila. Cell cycle (Georgetown, Tex). 2011; 10:904-911.
28. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K, Criollo A, Galluzzi L, Malik SA, Vitale I, Michaud M, Madeo F, Tavernarakis N, et al. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell death amp; disease. 2010; 1:e10.
29. Wu RE, Huang WC, Liao CC, Chang YK, Kan NW and Huang CC. Resveratrol protects against physical fatigue and improves exercise performance in mice. Molecules (Basel, Switzerland). 2013; 18:4689-4702.
30. Momken I, Stevens L, Bergouignan A, Desplanches D, Rudwill F, Chery I, Zahariev A, Zahn S, Stein TP, Sebedio JL, Pujos-GuillotE, Falempin M, Simon C, et al. Resveratrol prevents the wastingdisorders of mechanical unloading by acting as a physical exercise mimetic in the rat. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2011; 25:3646-3660.
31. Trepanowski JF, Canale RE, Marshall KE, Kabir MM and Bloomer RJ. Impact of caloric and dietary restriction regimens on markers of health and longevity in humans and animals: a summary of available findings. Nutr J. 2011; 10:107.
32. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, Nieman DC and Swain DP. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance forprescribing exercise. Med Sci Sports Exerc. 2011; 43:1334-1359.
33. Gurd BJ, Perry CG, Heigenhauser GJ, Spriet LL and Bonen A. High-intensity interval training increases SIRT1 activity in human skeletal muscle. Applied Physiology, Nutrition, and Metabolism. 2010; 35:350-357.
34. Blagosklonny MV. Hormesis does not make sense except in the light of TOR-driven aging. Aging (Albany NY). 2011; 3:1051-1062.
35. Chen YL, Huang CY, Lee SD, Chou SW, Hsieh PS, Hsieh CC, Huang YG and Kuo CH. Discipline-specific insulin sensitivity in athletes. Nutrition. 2009; 25:1137-1142.
36. Leddy JJ and Izzo J. Hypertension in athletes. Journal of clinical hypertension (Greenwich, Conn). 2009; 11:226-233.
37. Blagosklonny MV. Answering the ultimate question "what is the proximal cause of aging?". Aging (Albany NY). 2012; 4:861-877.
38. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1a. Cell. 2006; 127:1109-1122.
39. Wagner PD. New ideas on limitations to VO2max. Exerc Sport Sci Rev. 2000; 28:10-14.
40. Wong RH, Howe PR, Buckley JD, Coates AM, Kunz I and Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis. 2011; 21:851-856.
41. Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, Wilde A and Haskell CF. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. American Journal of Clinical Nutrition. 2010; 91:1590-1597.
42. Wong RH, Berry NM, Coates AM, Buckley JD, Bryan J, Kunz I and Howe PR. Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. Journal of hypertension. 2013; in press.
43. Levine BD. .VO2max: what do we know, and what do we still need to know? J Physiol. 2008; 586:25-34.
44. Joyner MJ and Coyle EF. Endurance exercise performance: the physiology of champions. J Physiol. 2008; 586:35-44.
45. Bonacci J, Chapman A, Blanch P and Vicenzino B. Neuromuscular adaptations to training, injury and passive interventions: implications for running economy. Sports Med. 2009; 39:903-921.
46. Hagan RD, Upton SJ, Wong L and Whittam J. The effects of aerobic conditioning and/or caloric restriction in overweight men and women. Med Sci Sports Exerc. 1986; 18:87-94.
47. Ekblom B and Berglund B. Effect of erythropoietin administration on mammal aerobic power. Scand J Med Sci Sports. 1991; 1:88-93.
48. Russell G, Gore CJ, Ashenden MJ, Parisotto R and Hahn AG. Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise. Eur J Appl Physiol. 2002; 86:442-449.
49. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, et al. Repeat Dose Study of the Cancer Chemopreventive Agent Resveratrol in Healthy Volunteers: Safety, Pharmacokinetics, and Effect on the Insulin-like Growth Factor Axis. Cancer Res. 2010; 70:9003-9011.
50. Imam AP and Halpern GM. Uses, adverse effects of abuse of corticosteroids. Part I. Allergologia et immunopathologia. 1994; 22:250-260.
51. Peltz L, Gomez J, Marquez M, Alencastro F, Atashpanjeh N, Quang T, Bach T and Zhao Y. Resveratrol exerts dosage and duration dependent effect on human mesenchymal stem cell development. PLoS One. 2012; 7:e37162.
52. Mrazek DA and Lerman C. Facilitating clinical implementation of pharmacogenomics. Jama. 2011; 306:304-305.
53. Wilke RA and Dolan ME. Genetics and variable drug response. Jama. 2011; 306:306-307.
54. Clark SJ, Falchi M, Olsson B, Jacobson P, Cauchi S, Balkau B, Marre M, Lantieri O, Andersson JC, Jernas M, Aitman TJ, Richardson S, Sjostrom L, et al. Association of sirtuin 1 (SIRT1) gene SNPs and transcript expression levels with severe obesity. Obesity (Silver Spring). 2012; 20:178-185.
55. Garaulet M, Esteban Tardido A, Lee YC, Smith CE, Parnell LD and Ordovas JM. SIRT1 and CLOCK 3111T> C combined genotype is associated with evening preference and weight loss resistance in a behavioral therapy treatment for obesity. Int J Obes (Lond). 2012; 36:1436-1441.
56. Spencer-Jones NJ, Ge D, Snieder H, Perks U, Swaminathan R, Spector TD, Carter ND and O'Dell SD. AMP-kinase alpha2 subunit gene PRKAA2 variants are associated with total cholesterol, lowdensity lipoprotein-cholesterol and high-density lipoproteincholesterol in normal women. J Med Genet. 2006; 43:936-942.
57. Horikoshi M, Hara K, Ohashi J, Miyake K, Tokunaga K, Ito C, Kasuga M, Nagai R and Kadowaki T. A polymorphism in the AMPKalpha2 subunit gene is associated with insulin resistance and type 2 diabetes in the Japanese population. Diabetes. 2006;55:919-923.
58. Shimoyama Y, Mitsuda Y, Tsuruta Y, Suzuki K, Hamajima N and Niwa T. SIRTUIN 1 gene polymorphisms are associated with cholesterol metabolism and coronary artery calcification in Japanese hemodialysis patients. Journal of renal nutrition: the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 2012; 22:114-119.
59. Gallina S, Di Francescomarino S, Di Mauro M, Izzicupo P,D'Angelo E, D'Amico MA, Pennelli A, Amicarelli F and Di Baldassarre A. NAD(P)H oxidase p22(phox) polymorphism and cardiovascular function in amateur runners. Acta Physiol (Oxf). 2012; 206:20-28.
60. Genius J, Grau AJ and Lichy C. The C242T polymorphism of the NAD(P)H oxidase p22phox subunit is associated with an enhanced risk for cerebrovascular disease at a young age. Cerebrovasc Dis. 2008; 26:430-433.
61. Channon KM and Guzik TJ. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol. 2002; 53:515-524.
62. Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, Saxena R, Fowler S, Shuldiner AR, Knowler WC, Altshuler D and Florez JC. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes. 2010; 59:2672-2681.
63. Massudi H, Grant R, Braidy N, Guest J, Farnsworth B and Guillemin GJ. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012; 7:e42357.
64. Villanova L, Vernucci E, Pucci B, Pellegrini L, Nebbioso M, Mauri C, Marfe G, Spataro A, Fini M, Banfi G, Russo MA and Tafani M. Influence of age and physical exercise on Sirtuin activity in humans. J Biol Regul Homeost Agents. 2013; 27:497-507.
65. Joseph AM, Adhihetty PJ, Buford TW, Wohlgemuth SE, Lees HA, Nguyen LM, Aranda JM, Sandesara BD, Pahor M, Manini TM, Marzetti E and Leeuwenburgh C. The impact of aging on mitochondrial function and biogenesis pathways in skeletal muscle of sedentary high- and low-functioning elderly individuals. Aging Cell. 2012; 11:801-809.
66. Gabler NB, French B, Strom BL, Liu Z, Palevsky HI, Taichman DB, Kawut SM and Halpern SD. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest. 2012; 141:20-26.
67. Draznin B, Wang C, Adochio R, Leitner JW and Cornier MA. Effect of dietary macronutrient composition on AMPK and SIRT1 expression and activity in human skeletal muscle. Horm Metab Res. 2012; 44:650-655.
68. Kitada M, Kume S, Takeda-Watanabe A, Tsuda SI, Kanasaki K and Koya D. Calorie restriction in overweight males ameliorates obesity-related metabolic alterations and cellular adaptations through anti-aging effects, possibly including AMPK and SIRT1 activation. Biochim Biophys Acta. 2013; 1830:4820-4827.
69. Bode LM, Bunzel D, Huch M, Cho GS, Ruhland D, Bunzel M, Bub A, Franz CM and Kulling SE. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am J Clin Nutr. 2013; 97:295-309.
70. Johnson JJ, Nihal M, Siddiqui IA, Scarlett CO, Bailey HH, Mukhtar H and Ahmad N. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol Nutr Food Res. 2011; 55:1169-1176.
71. Ghanim H, Sia CL, Korzeniewski K, Lohano T, Abuaysheh S, Marumganti A, Chaudhuri A and Dandona P. A resveratrol and polyphenol preparation suppresses oxidative and inflammatory stress response to a high-fat, high-carbohydrate meal. J Clin Endocrinol Metab. 2011; 96:1409-1414.
72. Smoliga JM, Vang O and Baur JA. Challenges of translating basic research into therapeutics: resveratrol as an example. J Gerontol A Biol Sci Med Sci. 2012; 67:158-167.
73. Almeida L, Vaz-da-Silva M, Falcao A, Soares E, Costa R, Loureiro AI, Fernandes-Lopes C, Rocha J-F, Nunes T, Wright L and Soares-da-Silva P. Pharmacokinetic and safety profile of transresveratrol in a rising multiple-dose study in healthy volunteers. Molecular Nutrition and Food Research. 2009; 53:S7-15.
74. Boocock DJ, Faust GES, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP and Brenner DE. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemoprotective agent. Cancer Epidemiology, Biomarkers amp; Prevention. 2007; 16:1246-1252.
75. Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi PP, Fogliano V and Marchell R. Bioavailability of transresveratrol from red wine in humans. Molecular Nutrition and Food Research. 2005; 49:495-504.
76. Sanna V, Roggio AM, Siliani S, Piccinini M, Marceddu S, Mariani A and Sechi M. Development of novel cationic chitosanandanionic alginate-coated poly(D,L-lactide-co-glycolide) nanoparticles for controlled release and light protection of resveratrol. Int J Nanomedicine. 2012; 7:5501-5516.
77. Ansari KA, Vavia PR, Trotta F and Cavalli R. Cyclodextrin- Based Nanosponges for Delivery of Resveratrol: In Vitro Characterisation, Stability, Cytotoxicity and Permeation Study. AAPS PharmSci. 2011; 12:279-286.
78. Renaud S and deLorgeril M. Wine, alocohol, platelets, and the French paradox for coronary heart disease. Lancet. 1992; 339:1523-1526.
79. Hart N, Sarga L, Csende Z, Koltai E, Koch LG, Britton SL, Davies KJ, Kouretas D, Wessner B and Radak Z. Resveratrol enhances exercise training responses in rats selectively bred for high running performance. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association. 2013; Epub ahead of print.
80. Kim HJ, Kim IK, Song W, Lee J and Park S. The synergic effect of regular exercise and resveratrol on kainate-induced oxidative stress and seizure activity in mice. Neurochemical research. 2013; 38:117-122.
81. Dolinsky VW, Jones KE, Sidhu RS, Haykowsky M, Czubryt MP, Gordon T and Dyck JR. Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats. The Journal of physiology. 2012; 590:2783-2799.
82. Lettieri-Barbato D, Tomei F, Sancini A, Morabito G and Serafini M. Effect of plant foods and beverages on plasma nonenzymatic antioxidant capacity in human subjects: a metaanalysis. Br J Nutr. 2013; 109:1544-1556.
83. Newby AC. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005; 85:1-31.
84. Aird WC. Endothelium in health and disease. Pharmacol Rep. 2008; 60:139-143.
85. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340:115-126.
86. Channell MM, Paffett ML, Devlin RB, Madden MC and Campen MJ. Circulating factors induce coronary endothelial cell activation following exposure to inhaled diesel exhaust and nitrogen dioxide in humans: Evidence from a novel translational in vitro model. Toxicol Sci. 2012.\; 127:179-186.
87. Robertson S, Colombo ES, Lucas SN, Hall PR, Febbraio M, Paffett ML and Campen MJ. CD36 Mediates Endothelial Dysfunction Downstream of Circulating Factors Induced by O3 Exposure. Toxicol Sci. 2013; 134:304-311.
88. Smith BM, Kawut SM, Bluemke DA, Basner RC, Gomes AS, Hoffman E, Kalhan R, Lima JA, Liu CY, Michos ED, Prince MR, Rabbani L, Rabinowitz D, et al. Pulmonary hyperinflation and left ventricular mass: the Multi-Ethnic Study of Atherosclerosis COPD Study. Circulation. 2013; 127:1503-1511, 1511e1501-1506.
89. Lahousse L, van den Bouwhuijsen QJ, Loth DW, Joos GF, Hofman A, Witteman JC, van der Lugt A, Brusselle GG and Stricker BH. Chronic obstructive pulmonary disease and lipid core carotid artery plaques in the elderly: the Rotterdam Study. American journal of respiratory and critical care medicine. 2013; 187:58-64.
90. Dumaine RL, Montalescot G, Steg PG, Ohman EM, Eagle K and Bhatt DL. Renal function, atherothrombosis extent, and outcomes in high-risk patients. American heart journal. 2009; 158:141-148 e141.
91. Palsamy P and Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta. 2011; 1812:719-731.
92. Jing YH, Chen KH, Yang SH, Kuo PC and Chen JK. Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling. Diabetes/metabolism research and reviews. 2010; 26:212-222.
93. Zheng Z, Xu X, Zhang X, Wang A, Zhang C, Huttemann M, Grossman LI, Chen LC, Rajagopalan S, Sun Q and Zhang K. Exposure to ambient particulate matter induces a NASH-like phenotype and impairs hepatic glucose metabolism in an animal model. J Hepatol. 2013; 58:148-154.
94. Laing S, Wang G, Briazova T, Zhang C, Wang A, Zheng Z, Gow A, Chen AF, Rajagopalan S, Chen LC, Sun Q and Zhang K. Airborne particulate matter selectively activates endoplasmic reticulum stress response in the lung and liver tissues. Am J Physiol Cell Physiol. 2010; 299:C736-749.
95. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012; 15:675-690.
96. Allard JS, Heilbronn LK, Smith C, Hunt ND, Ingram DK, Ravussin E and de Cabo R. In vitro cellular adaptations of indicators of longevity in response to treatment with serum collected from humans on calorie restricted diets. PLoS One. 2008; 3:e3211.
97. de Cabo R, Furer-Galban S, Anson RM, Gilman C, Gorospe M and Lane MA. An in vitro model of caloric restriction. Exp Gerontol. 2003; 38:631-639.
98. Conti V, Corbi G, Russomanno G, Simeon V, Ferrara N, Filippelli W, Limongelli F, Canonico R, Grasso C, Stiuso P, Dicitore A and Filippelli A. Oxidative stress effects on endothelial cells treated with different athletes' sera. Med Sci Sports Exerc. 2012; 44:39-49.